Prot#VK2809-202: A Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of VK2809 Administered for 52 Weeks Followed by a 4-Week Off-Drug Phase in Subjects with Biopsy Proven Non-Alcoh

Project: Research project

Project Details

StatusActive
Effective start/end date3/4/203/4/23

Funding

  • Covance Inc. (Prot#VK2809-202)
  • Viking Therapeutics, Inc. (Prot#VK2809-202)